A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate

Susana Lousada-Dietrich; Prajakta S Jogdand; Søren Jepsen; Vera Manuel Valadão Vaz dos Santos Pinto; Sisse B Ditlev; Michael Christiansen; Severin Olesen Larsen; Christopher B Fox; Vanitha S Raman; Randall F Howard; Thomas S Vedvick; Gregory Ireton; Darrick Carter; Steven G Reed; Michael Theisen

doi:10.1016/j.vaccine.2011.02.022

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate

Susana Lousada-Dietrich, Prajakta S Jogdand, Søren Jepsen, Vera Manuel Valadão Vaz dos Santos Pinto, Sisse B Ditlev, Michael Christiansen, Severin Olesen Larsen, Christopher B Fox, Vanitha S Raman, Randall F Howard, Thomas S Vedvick, Gregory Ireton, Darrick Carter, Steven G Reed, Michael Theisen

44 Citationer (Scopus)

Abstract

GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant vehicles and Toll-like receptor (TLR) agonists in CB6F1 mice to identify an improved formulation of GMZ2 suitable for further human clinical studies. GMZ2 formulated in an oil-in-water emulsion plus the synthetic TLR4 agonist GLA elicits the highest (a) vaccine-specific IgG2a and total IgG titers, (b) parasite-specific IFA titers, (c) levels of Type 1 cytokine responses (IFN-γ), and (d) number of long-lived-plasma cells (LLPC) secreting antibodies against both the GMZ2 fusion and its two components. Thus, GLA helps to elicit a vaccine-specific Type 1 antibody profile together with high levels of LLPC, both of which are thought to be essential for the development of long-term protective immunity against clinical malaria.

Originalsprog	Engelsk
Tidsskrift	Vaccine
Vol/bind	29
Udgave nummer	17
Sider (fra-til)	3284-92
Antal sider	9
DOI	https://doi.org/10.1016/j.vaccine.2011.02.022
Status	Udgivet - 12 apr. 2011

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.vaccine.2011.02.022

Citationsformater

Lousada-Dietrich, S., Jogdand, P. S., Jepsen, S., Valadão Vaz dos Santos Pinto, V. M., Ditlev, S. B., Christiansen, M., Larsen, S. O., Fox, C. B., Raman, V. S., Howard, R. F., Vedvick, T. S., Ireton, G., Carter, D., Reed, S. G., & Theisen, M. (2011). A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine, 29(17), 3284-92. https://doi.org/10.1016/j.vaccine.2011.02.022

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate. / Lousada-Dietrich, Susana; Jogdand, Prajakta S; Jepsen, Søren et al.

I: Vaccine, Bind 29, Nr. 17, 12.04.2011, s. 3284-92.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Lousada-Dietrich, S, Jogdand, PS, Jepsen, S, Valadão Vaz dos Santos Pinto, VM, Ditlev, SB, Christiansen, M, Larsen, SO, Fox, CB, Raman, VS, Howard, RF, Vedvick, TS, Ireton, G, Carter, D, Reed, SG & Theisen, M 2011, 'A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate', Vaccine, bind 29, nr. 17, s. 3284-92. https://doi.org/10.1016/j.vaccine.2011.02.022

@article{f8ec19619ca64a05bb68e94bd491c726,

title = "A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate",

abstract = "GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant vehicles and Toll-like receptor (TLR) agonists in CB6F1 mice to identify an improved formulation of GMZ2 suitable for further human clinical studies. GMZ2 formulated in an oil-in-water emulsion plus the synthetic TLR4 agonist GLA elicits the highest (a) vaccine-specific IgG2a and total IgG titers, (b) parasite-specific IFA titers, (c) levels of Type 1 cytokine responses (IFN-γ), and (d) number of long-lived-plasma cells (LLPC) secreting antibodies against both the GMZ2 fusion and its two components. Thus, GLA helps to elicit a vaccine-specific Type 1 antibody profile together with high levels of LLPC, both of which are thought to be essential for the development of long-term protective immunity against clinical malaria.",

author = "Susana Lousada-Dietrich and Jogdand, {Prajakta S} and S{\o}ren Jepsen and {Valad{\~a}o Vaz dos Santos Pinto}, {Vera Manuel} and Ditlev, {Sisse B} and Michael Christiansen and Larsen, {Severin Olesen} and Fox, {Christopher B} and Raman, {Vanitha S} and Howard, {Randall F} and Vedvick, {Thomas S} and Gregory Ireton and Darrick Carter and Reed, {Steven G} and Michael Theisen",

year = "2011",

month = apr,

day = "12",

doi = "10.1016/j.vaccine.2011.02.022",

language = "English",

volume = "29",

pages = "3284--92",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "17",

}

TY - JOUR

T1 - A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate

AU - Lousada-Dietrich, Susana

AU - Jogdand, Prajakta S

AU - Jepsen, Søren

AU - Valadão Vaz dos Santos Pinto, Vera Manuel

AU - Ditlev, Sisse B

AU - Christiansen, Michael

AU - Larsen, Severin Olesen

AU - Fox, Christopher B

AU - Raman, Vanitha S

AU - Howard, Randall F

AU - Vedvick, Thomas S

AU - Ireton, Gregory

AU - Carter, Darrick

AU - Reed, Steven G

AU - Theisen, Michael

PY - 2011/4/12

Y1 - 2011/4/12

N2 - GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant vehicles and Toll-like receptor (TLR) agonists in CB6F1 mice to identify an improved formulation of GMZ2 suitable for further human clinical studies. GMZ2 formulated in an oil-in-water emulsion plus the synthetic TLR4 agonist GLA elicits the highest (a) vaccine-specific IgG2a and total IgG titers, (b) parasite-specific IFA titers, (c) levels of Type 1 cytokine responses (IFN-γ), and (d) number of long-lived-plasma cells (LLPC) secreting antibodies against both the GMZ2 fusion and its two components. Thus, GLA helps to elicit a vaccine-specific Type 1 antibody profile together with high levels of LLPC, both of which are thought to be essential for the development of long-term protective immunity against clinical malaria.

AB - GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant vehicles and Toll-like receptor (TLR) agonists in CB6F1 mice to identify an improved formulation of GMZ2 suitable for further human clinical studies. GMZ2 formulated in an oil-in-water emulsion plus the synthetic TLR4 agonist GLA elicits the highest (a) vaccine-specific IgG2a and total IgG titers, (b) parasite-specific IFA titers, (c) levels of Type 1 cytokine responses (IFN-γ), and (d) number of long-lived-plasma cells (LLPC) secreting antibodies against both the GMZ2 fusion and its two components. Thus, GLA helps to elicit a vaccine-specific Type 1 antibody profile together with high levels of LLPC, both of which are thought to be essential for the development of long-term protective immunity against clinical malaria.

U2 - 10.1016/j.vaccine.2011.02.022

DO - 10.1016/j.vaccine.2011.02.022

M3 - Journal article

C2 - 21349366

SN - 0264-410X

VL - 29

SP - 3284

EP - 3292

JO - Vaccine

JF - Vaccine

IS - 17

ER -

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - A GLURP-MSP3 fusion protein malaria vaccine candidate

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater